Lexaria Bioscience Corp.
LEXX
$1.35
$0.032.27%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.55% | 173.62% | 8.11% | 625.00% | 54.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.55% | 173.62% | 8.11% | 625.00% | 54.86% |
| Cost of Revenue | -43.75% | -- | -- | -- | -69.62% |
| Gross Profit | 23.69% | 173.62% | 29.23% | 747.95% | 78.88% |
| SG&A Expenses | 29.19% | 134.70% | 51.94% | -11.99% | -24.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.77% | 114.74% | -26.29% | -39.50% | -28.04% |
| Operating Income | -136.21% | -112.94% | 27.41% | 49.53% | 32.81% |
| Income Before Tax | -128.41% | -75.07% | 25.14% | 50.20% | 33.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -128.41% | -75.07% | 25.14% | 50.20% | 33.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -49.12% | -81.44% | -78.51% | -74.40% | -57.46% |
| Net Income | -129.26% | -76.29% | 24.87% | 49.97% | 32.84% |
| EBIT | -136.21% | -112.94% | 27.41% | 49.53% | 32.81% |
| EBITDA | -139.33% | -127.35% | 27.28% | 49.80% | 33.54% |
| EPS Basic | -24.48% | 9.03% | 65.07% | 72.35% | 55.85% |
| Normalized Basic EPS | -29.94% | -12.01% | 65.85% | 71.54% | 55.82% |
| EPS Diluted | -24.48% | 9.03% | 65.07% | 72.35% | 55.85% |
| Normalized Diluted EPS | -29.94% | -12.01% | 65.85% | 71.54% | 55.82% |
| Average Basic Shares Outstanding | 84.15% | 93.78% | 115.11% | 80.90% | 52.10% |
| Average Diluted Shares Outstanding | 84.15% | 93.78% | 115.11% | 80.90% | 52.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
